|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Antidyslipidemics - The competitive cost-conscious antidyslipidemics market presents challenges
Datamonitor, July 2007, Pages: 188
Introduction
The restrictive, highly competitive antidyslipidemic market is going to become even further genericized, which will add to the challenges that drug makers are facing. Despite over 300m people being eligible for antidyslipidemic treatment, there is still a lot of under-diagnosis and under-treatment, but it will be a major issue capturing all the eligible population.
Scope
Assessment of each of the seven major markets, key drivers for growth and resistors to growth Overview of the main opportunities and threats in each of the seven major markets Forecast analysis including the key events, among them new product launches, major clinical trials and patent expiries. Overview of two case studies (on CETP inhibitors and on the second wave of patent expiries) including worst and best case scenarios.
Highlights
Despite over 300m people being eligible for treatment in seven major markets, as well as the recommended treatment goals capturing more patients and promoting more aggressive therapy, there is a lot of under-diagnosis and under-treatment. Cost-saving policies further limit the patient potential for branded agents. Lowering of LDL-C treatment goals cannot counteract the impact of cost-saving policies, and does not guarantee a revenue stream for branded agents. This is why there are currently several outcome trials that regard the potential of branded agents (Crestor, Vytorin) in new indications/patient groups, e.g. heart failure and renal disease. Branded statins market share is diminishing. Due to the patent expiries of statins that have taken place in the past five years (especially that of Zocor) and those going to take place in the near future (especially that of Lipitor) the branded statins are losing their market share rapidly.
Reasons to Purchase
Understand key drivers and predict the future performance of key compounds Optimize sales and marketing strategy to counter market threats Develop commercial strategies across the seven major markets
Customers who bought this item also bought
Strategic Perspectives: Antidyslipidemics - Current Market is not Conducive for Growth
Commercial Insight: Antidyslipidemics - Branded Statins Beware, Generics Are Amongst You
Forecast Insight: Dyslipidemia - Genericization and Negative Trial Data Drive Market Shrinking
Pipeline Insight: Dyslipidemia - Pipeline Agents Unlikely To Rejuvenate The Market
Forecast Insight: Antihypertensives - Key Patent Expiries Prevent Market Growth
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
Dyslipidemia: Opportunities in Cardiovascular Risk Reduction
Generic Drug Market in Canada
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products
Dyslipidemia - Statins Dominate Treatment Pathway - For Now
Commercial Insight: Antidyslipidemics - Statins Hit the Brakes on Market Growth
Antidyslipidemics - Genericization and Negative Trial Data Drive Market Shrinkage
|
|
|
|
